PDS Biotechnology Corp (NAS:PDSB)
$ 3.51 -0.32 (-8.36%) Market Cap: 128.74 Mil Enterprise Value: 96.03 Mil PE Ratio: 0 PB Ratio: 4.44 GF Score: 35/100

PDS Biotechnology Corp at Noble Capital Markets Takeaway Series on Channelchek- J.P. Morgan Healthcare Conference Transcript

Jan 26, 2023 / 03:00PM GMT
Release Date Price: $9.35 (-2.81%)
Operator

Welcome to the Channelchek Takeaway Series. This program is provided for informational purposes only, and none of its content should be interpreted as a recommendation or solicitation to buy or sell securities. Investment decisions must be made by you or with the support of your financial advisor. The complete disclosure statement follows each presentation.

PDS Biotechnology, NASDAQ ticker symbol, PDSB. is a clinical-stage immunotherapy company, developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on their proprietary Versamune and Infectimune T cell-activating technology platforms. Joining us today is PDS Biotech President and CEO, Frank Bedu-Addo. Following a discussion of the company pipeline, Frank is joined by Noble's senior research analysts, Robert LeBoyer, for Q&A. And now, here's Robert and Frank.

Robert LeBoyer
Noble Capital Markets, Inc. - Analyst

With me here today is Dr. Frank Bedu-Addo, President and CEO of PDS Biotech. Biotechnology industry has gone through a long decline, probably the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot